GMMG-HD6

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

May 18, 2019 → Aug 3, 2026

Cited window

Jun 12, 2020 → Aug 3, 2026

Retrieved

Oct 30, 2026

Title

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Registry

NCT02495922

Study IDs

GMMG HD6

Sponsor

University of Heidelberg Medical Center

Design

Phase 3 · Interventional, randomized, parallel

Status

Completed

Enrollment

564 actual

Registered

2015-07-13

Start

2015-06

Primary completion

2021-06-24 actual

Primary endpoint

the best of four treatment strategies regarding Progression Free Survival (PFS)

Interventions

4 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –81 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition do not represent all HCPs or all public discussion. The report cannot estimate prevalence or consensus.
• –Reposts, quoted posts and podcast/video versions may repeat the same view and are not independent endorsements.
• –Some potentially relevant passages were not fully assessed, and an additional view in the late-relapse video could not be included with sufficient supporting detail. Further qualifications or practical concerns may be missing.
• –The podcast version does not identify who spoke the elotuzumab passage. Its statements remain unattributed despite a named speaker in the video version.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –A speaker's involvement in GMMG-HD6 is described by the source. Those views should not be counted as an independent external assessment of the trial.
• –The maintenance, MRD, related FISH and quality-of-life discussions that do not name GMMG-HD6 are contextual to its clinical question, not additional trial results.
• –The Elo/KRd MRD figures, FORTE interpretations, SWOG S1211 comparison, Perseus comparison and IRMMa analyses must retain their own study, endpoint and setting.
• –A protocol publication was available, but no protocol document was listed in the registry. Prospective expectations in the protocol are not observed outcomes.
• –Not all identified regulatory material was reviewed. Historical treatment-line and insurer experiences do not establish all current access requirements.
• –The absence of substantive clinician commentary on the trial's grade 3-or-higher toxicity comparison does not establish a favorable safety interpretation.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "GMMG-HD6" (NCT02495922), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "gmmg-hd6-02495922". If you cannot make requests, read https://www.erudio.com/reports/gmmg-hd6-nct02495922.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT02495922", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct02495922 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/gmmg-hd6-nct02495922.json
curl https://www.erudio.com/reports/gmmg-hd6-nct02495922.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "gmmg-hd6-02495922" })